News
Voices of Hodgkin’s Blog
Voices of Hodgkin’s Blog

Doxorubicin Exposure and Breast Cancer Risk in Survivor of Adolescent and Adult Hodgkin Lymphoma

This research paper takes a look at the risk of breast cancer from doxorubicin exposure in female survivors of Hodgkin lymphoma who are between the ages of 15-50 years of age and five years post treatment. The period of treatment was between 1975 and 2008. The study was first presented in 2021 at the ASCO Annual Meeting.

Of note is that the authors found an increased risk of breast cancer in this cohort independent of whether or not radiation was also a part of the treatment protocol. Their conclusions include this very important point- one that we will continue to advocate for with fervor.

Patient Webinar: Advances in Robotic Heart Valve Surgery

During this special patient webinar, you will learn critical insights about new advances in minimally-invasive, robotic heart valve surgery. The featured speakers are Dr. Pavan Atluri, Director of Minimally Invasive and Robotic Cardiac Surgery, and Dr. Michael Ibrahim, Director of Reconstructive Valve Surgery, at Penn Medicine.

What Does it Take to Harmonize the World’s Hodgkin Lymphoma Data?

In the first episode of The HemOnc Pulse in 2024, the lead researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium discuss the immense labor and fortitude it took to successfully launch the consortium, which includes a global team of diverse experts focused on the prognosis, epidemiology, treatment, survivorship, and health outcomes in patients with Hodgkin lymphoma.

Significant Progression-Free Survival in Stage III/IV Classic Hodgkin Lymphoma

A Phase III trial has demonstrated that patients with advanced Stage III/IV classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.